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PHENYLBUTYL NITRONE COMPOSITIONS 
AND METHODS FOR PREVENTION OF 
GASTRIC ULCERATION 
Matter enclosed in heavy brackets [ ] appears in the 
original patent but forms no part of this reissue speci? 
cation; matter printed in italics indicates the additions 
made by reissue. 
The United States Government has certain rights in this 
invention by virtue of grants from the National Institutes of 
Health. 
BACKGROUND OF THE INVENTION 
This is a continuation-in-part of U.S. Ser. No. 07/422,651 
entitled “Phenyl Butyl Nitrone Compositions for Treatment 
of Oxidative Tissue Damage” ?led Oct. 17, 1989 by John M. 
Carney and Robert A. Floyd, now U.S. Pat‘. No. 5,025,032. 
This is generally in the area of compositions and methods 
for use thereof for the treatment and prevention of gas 
trointestinal ulceration resulting from the use of nonsteroidal 
anti-in?ammatory compounds, wherein the active corn~ 
pounds are phenyl butylnitrone (PBN) or derivatives 
thereof. 
Gastric ulceration is among the most important of adverse 
reactions from aspirin and nonsteroidal anti-in?ammatory 
drugs (NSAIDS). The currently accepted explanation for 
NSAID-induced gastric ulceration is that NSAIDS inhibit 
synthesis of cytoprotective prostaglandins, as reviewed by 
Whittle, B. R., and J. R. Vane. Arch. Toxicol. Suppl 
7:315-322 (1984). This hypothesis is supported by the 
demonstration that exogenous prostaglandins protect from 
NSAID-related gastric ulcers by Graham, D. Y., et al. Lancet 
2: 1277-1280 (1088), but challenged by recent studies show 
ing that NSAIDS can inhibit gastric prostaglandin produc 
tion without causing ulceration, as reported by Rainsford, K. 
D., et al. Scand. J. Gastroenterol. 19 (Suppl 10l):35—68 
(1984); Ligumsky, M., et a1. Gastroenterology 84:756-—76l 
(1985); and Rainsford, K. D., “Relationship between drug 
absorption, inhibition of cyclo-oxygenase and lipoxygenase 
pathways and the development of gastric mucosal damage of 
non-steroidal anti-in?ammatory drugs in rats and pigs". in 
Advances in Prostaglandins, Leukotrienes and Lipoxins. M. 
J. Bailey, editor. Plenum Press, New York, 639-653 (1985). 
Thus, the cause of NSAlD-induced gastric ulceration 
remains controversial, as reviewed by Rainsford, K. D. 
Toxicologic Pathol. l6:251—259 (1988). 
Free radicals have been postulated to be mediators of 
tissue injury including that brought on by ischernical reper 
fusion damage. Important production sites of the oxygen 
free radicals superoxide (02-) and hydroxyl (OH) radicals 
are the mitochondrial respiratory chain and the reaction 
sequences catalyzed by cyclooxygenasc and lipoxygenase. 
However, radicals are also formed during autoxidation of 
many compounds (e.g., catecholamines). Ischemic events in 
tissue causes a spurt of free-radical formation. This may be 
due to oxidation of polyenoic free fatty acids, release and 
reuptake of catecholamines, and oxidation of xanthine and 
hypoxanthine by xanthine oxidase. Although all these events 
occur during recirculation, when the O2 supply is restored 
after ischemia, they represent metabolic cascades triggered 
by agonistreceptor interactions, energy failure, and/or cal 
cium in?ux during the insult. Although free radical forma 
tion is a likely cause of ischemic damage, it has been di?icult 
to directly demonstrate that such formation occurs and/or 
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that it is su?iciently pronounced to overwhelm the antioxi 
dative defense of the tissue, Curran, et al., Mol. Cell. Biol. 
5, 167-172 (1985). In recent years, however, evidence has 
been obtained that ischemia may cause conjugated dienes 
and malondialdehyde to accumulate in the tissue. Even so, 
it remains to be conclusively shown that free-radical damage 
to unsaturated acyl chains in phospholipids, to protein, or to 
nucleic acids constitutes an important role in the ischemic 
necrosis. At present, the evidence is relatively strong for an 
involvement of free-radical mechanisms in vascular injury, 
and in damage a?ecting nerve and glial cells. 
Although no drugs are currently approved for clinical use 
in treating tissue damage due to ischemia, several com 
pounds have been proposed as potentially being effective. 
Mannitol, an oxygen scavenger, has been added to reperfu 
sion media to limit damage to organs for transplantation. 
Superoxide disrnutase (SOD) has been suggested as a means 
for limiting in vivo oxidative damage. The most promising 
compounds that interfere with peroxidation generation are 
the lazaroides. modi?ed prednisones, described by J. M. 
McCall, Acta Anesthesia Belgica, First Antwerp int. Trauma 
Symp., which have been reported to be e?icacious if given 
during or after ischemia. White and Aust and co-workers, 
Adv. Free Radical Biol. Med. l,l—l7 (1985), and Babbs, 
Resuscitation l3, l65—l73 (1986), have demonstrated that 
iron chelators protect animals from ischemia/reperfusion 
injury. 
It is therefore an object of the present invention to provide 
composition and methods for use thereof which are useful in 
preventing or treating gastric ulcers resulting from the use of 
non-steroidal anti-in?ammatory compounds. 
It is a further object of the present invention to provide 
compositions and methods for use thereof which are useful 
in preventing or treating pain and fever in vivo resulting 
from infection and inflammation. 
SUMMARY OF THE INVENTION 
Compositions containing PBN, or active derivatives 
thereof, in a suitable pharmaceutical carrier for administra 
tion to a patient, are disclosed for treating or preventing 
gastric ulceration caused by ingestion of non-steroidal anti 
in?ammatories. The compositions have the following gen 
eral formula: 
H 0* 
\ / 
C=N+ 
/ \ 
X Y 
wherein: 
X is phenyl or 
(0R)n 
wherein R is H, 
0 0 
ll 
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and n is a whole integer from 1 to 5; or 
0 || 
NH——C—Z—; 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
wherein W is 
or Z; and 
Z is a C1 to CS straight or branched alkyl group. 
Based on animal studies, the dosage is in the range of 3 
to 300 mg/kg and is administered prior to, simultaneously, or 
shortly after ingestion of the NSAID compound(s). In the 
preferred embodiment, the range is between 10 and 30 
mg/kg, depending on the dosage unit required to protect the 
mucosa. The preferred method of administration is orally, 
alone or in combination with the non-steroidal anti-in?am 
matory. It is believed that the PBN is also useful alone for 
treatment or prevention of ulcers, aspects of diarrhea, gas 
tritis, esophagitis, ileitis, and possibly pain and fever in a 
manner analogous to analgesics such as aspirin and acetami 
nophen. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a comparison of the stomach from a piroxicam 
treated rat (right) to the stomach from a vehicle control 
treated rat (left). Piroxicam at 23 mg/kg caused prominent 
ulceration along the ridges of gastric rugae. 
FIG. 2 is a graph of % control ulceration from piroxicarn 
versus the % ulceration in the presence of free radical 
scavengers. The sul?iydryl scavenger dimethylthiourea 
(DMTU), 500 mg/kg i.p.) was given 24 hours and 1 hour 
before piroxicam. The sulfhydryl scavenger N-acetylcys 
teine (300 mg/kg), the hydroquinone acetaminophen (400 
mg/kg) and the spin-trap phenylbutyl nitrone (PBN, 30 
mg/kg) were given orally 1 hour before and along with 
piroxicam. The antioxidant butylated hydroxytoluene (BHT, 
25 mg/kg/day i.p. in corn oil) was given for three days 
before and again 1 hour before piroxicam. The % control 
ulceration is determined by averaging the ratios of cm2 
ulceration in control stomachs from rats given piroxicarn 
alone, and multiplyingxlOU. +P<0.0l compared to piroxi 
cam alone. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Gastric parietal cells have abundant mitochondria to gen 
erate the energy required for hydrogen ion secretion. Sali 
cylate and NSAIDS have long been recognized as uncou 
plers of mitochondrial oxidative phosphorylation, and 
aspirin decreases mucosal adenosine triphosphate (ATP) and 
20 
25 
35 
40 
45 
50 
60 
65 
4 
phospbhocreatine (PC) in isolated perfused gastric mucosa. 
Thus, aspirin and NSAIDS might be expected to produce 
changes in the energy state of gastric mucosa similar to those 
caused by ischemia, when ATP is depleted and then 
degraded to hypoxanthine, as discussed by McCord, I . M. N. 
Engl. J. Med. 312:158-163 (1985). Xanthine oxidase-me 
diated ischemia-reperfusion injury of the stomach has 
recently been reported as a cause of stress ulceration in 
hemorrhagic shock, as reported by Itoh, M., and P. H. Guth. 
Gastroenterology 88:1162-1167 (1985); Perry, M. A., et a1. 
Gastroenterology 90:362—367 (1986); and Smith, S. M., 
Gastroenterology 92:950-956 (1987). If aspirin and 
NSAIDS impair mitochondrial energy metabolism, the sub 
sequent breakdown of high energy purines to xanthine might 
also stimulate xanthine oxidase-mediated oxidant injury in 
gastric mucosa, resulting in ulceration. 
It has now been discovered that, further to the methods 
using PBN for the treatment and prevention of ischemic 
damage, including by decreasing or preventing ATP deple 
tion, described and claimed in U.S. Ser. N o. 07/422,651 ?led 
Oct. 17, 1989, PBN, and derivatives thereof having spin 
trapping activity, are useful in preventing or treating gastric 
ulceration resulting from ingestion of non-steroidal anti 
in?ammatories. As used herein, a free radical scavenger or 
spin-trap reagent is a molecule that will form a stable 
complex with a free radical. A free radical carbon trap is a 
molecule in which the free radical is localized on a carbon 
atom or a nitrogen atom. As a result of this chemical bond 
formation, the free radical is no longer damaging to the cell. 
u-phenyl t-butyl nitrone (PBN), and derivatives thereof, 
in a pharmaceutical vehicle suitable for administration to a 
patient, preferably by oral administration, are useful in 
preventing or reversing gastric ulceration caused by the use 
of non-steroidal anti-inflammatories (NSAID). PBN has a 
number of advantages in the treatment of gastric ulceration, 
especially its complete lack of a measurable effect on normal 
or uninjured cells. PBN is the preferred active compound at 
this time, although a number of derivatives are also useful, 
including hydroxy derivatives, especially 2-, 3- or 4-hy 
droxy PBN and mono-, di- and trihydroxy tert-butyl nitrone; 
esters, especially esters which release 2-, 3, or 4-hydrox 
yphenyl t-butyl nitrone such as the acetoxy derivative, 2-, 3-, 
or 4-carboxyphenyl t-butyl nitrone, such as the ethyl deriva 
tive, or phenyl hydroxybutyl nitrone, such as the acetoxy 
derivative; alkoxyl derivatives, especially lkoxyl derivatives 
which release 2-, or 4-hydroxyphenyl t-butyl nitrone, such 
as the methyl derivative; and acetarnide derivatives, espe 
cially acetarnide derivatives which release 2-, or 4 ami 
nophenyl t-butyl nitrone, such as the acetyl derivative; 
diphenyl nitrone (PPN) and the analogous diphenyl nitrone 
derivatives. As used herein, “PBN” refers to both ot-phenyl 
t-butyl nitrone and derivatives thereof, unless otherwise 
stated. The active agent in the compositions is N-tert-Butyl 
(x-phenylnitrone (PBN) or derivatives thereof that are spin 
trap reagents and in addition to chemical binding of free 
radicals, may also act to prevent ATP depletion of cells. 
The general formula for PBN and useful derivatives 
thereof is: 
Re. 35,213 
wherein: 
X is phenyl or 
(OR)n 
wherein R is H, 
0 0 
ll 
Y 
and n is a whole integer from 1 to 5; or 
0 
ll 
NH—C—Z—-, 
Y is tert-butyl group that can be hydroxylated or acety 
lated on one or more positions; phenyl; or 
OW 
wherein W is 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
The compositions can also contain other active agents, 
such as bu?‘ering agents such as antacids or inert carriers 
such as lactose. Examples of commonly used NSAIDs 
include aspirin, acetaminophen, ibuprofen, piroxicarn, 
naphroxen, ?ufenamic and methanamic acid and related 
nonsteroidal antiin?amrnatory compounds. 
Examples demonstrate the utility of the compositions in 
preventing or treating ulceration resulting from ingestion of 
NSAIDs. Exemplary dosages of PBN ranged from 3 to 300 
mg/kg of body weight in animals. The effective range of 
PBN in humans and other mammals is expected to be 
between approximately 10 and 300 mg/kg, preferably 
between 10 and 30 mg/kg body weight. The compositions 
can be effectively administered prior to, during or shortly 
after ingestion of NSAIDs, and prevent or decrease the 
extent of cellular damage. 
Since the trapping of endogenous free radicals is speci?c 
for only those cells that have been exposed to the conditions 
that result in the production of free radicals, the traps have 
little or no e?’ect on normal cells. The bene?cial effects 
occur only in injured cells, and do not require the presence 
of speci?c receptors, speci?c enzymes, and/or speci?c cell 
types. 
The PBN is preferably administered systemically, most 
preferably orally, since this is the most rapid and e?icient 
means for delivering the active compound to the site of free 
radical generation. The PBN may be administered at once, 
or may be divided into a number of smaller doses to be 
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administered at varying intervals of time. Other methods of 
administration can also be used, including subcutaneous, 
intravenous, and intraperitoneal administration. The pharv 
maceutical compositions should provide a dosage of PBN 
relative to the dosage of NSAID su?icient to protect the 
mucosa from the e?ect of the NSAID. The concentration of 
active compound in the drug composition will depend on 
absorption, inactivation, and excretion rates of the drug as 
well as other factors known to those skilled in the art. The 
compositions are administered prior to, at the same time as, 
or shortly after ingestion of the non-steroidal anti-in?am 
matories. The e?ective dosage may also be determined 
based on that amount required to prevent or reverse predis 
position of the cells to damage resulting from depletion of 
ATP (as demonstrated by in vivo NMR) and damage from 
free radical generation. It is to be noted that dosage values 
will also vary with the condition of the patient being treated. 
It is to be further understood that for any particular subject, 
speci?c dosage regimens should be adjusted over time 
according to the individual need and the professional judg 
ment of the person administering or supervising the admin 
istration of the compositions, and that the concentration 
ranges set forth herein are exemplary only and are not 
intended to limit the scope or practice of the claimed 
composition. 
A preferred mode of administration of the active com 
pound is in a form for oral delivery. Oral compositions will 
generally include an inert diluent or an edible carrier. 
Preferred pharmaceutical carriers for intravenous adminis— 
tration are saline or phosphate buffered saline at physiologi 
cal pH. Since PBN degrades at pH less than approximately 
3 to 4, it is preferred to administer the PBN at a pH of 4 or 
higher, or in combination with food or a bu?ering agent. For 
oral delivery, the PBN may be enclosed in capsules, com‘ 
pressed into tablets, microencapsulated, entrapped in lipo 
somes, in solution or suspension, alone or in combination 
with a substrate immobilizing material such as starch or 
poorly absorbable salts such as immodium. Pharmaceuti 
cally compatible binding agents, and/or adjuvant materials 
can be included as part of the composition. The tablets or, 
capsules may contain, for example, any of the following 
ingredients, or compounds of a similar nature: a binder such 
as microcrystalline cellulose, gum tragacanth or gelatin; an 
excipient such as starch or lactose, a disintegrating agent 
such as alginic acid, Primogel®, or corn starch; a lubricant 
such as magnesium stearate or Sterotes; a glidant such as 
colloidal silicon dioxide; a sweetening agent such as sucrose 
or saccharin; or a ?avoring agent such as peppermint, methyl 
salicylate, or orange ?avoring. When the dosage unit form is 
a capsule, it can contain, in addition to material of the above 
type, a liquid carrier such as a fatty oil. In addition, dosage 
unit forms can contain various other materials which modify 
the physical form of the dosage unit, for example, coatings 
of sugar, shellac, or other enterie agents. 
The present invention will be further understood with 
reference to the following non-limiting examples demon— 
strating methods for determining effectiveness of PBN 
administration for treatment or prevention and/or reversal of 
damage from NSAIDs. 
EXAMPLE 1: COMPARISON OF 
PIROXICAM-INDUCED ULCER WITH 
CONTROL. 
The following materials and methods were used in 
examples 1 and 2. 
Animal Experiments. 
Male Sprague-Dawley rats (Charles River, Wilmington, 
Mass.) weighing 300-325 g were housed individually in 
Re. 35,213 
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wire bottomed cages to prevent ingestion of hair and feces. 
Animals were maintained without food for 48 hours and 
without water for 24 hours prior to each experiment. Piroxi 
cam or aspirin and other NSAIDS were suspended in a 
vehicle of l% carboxymethylcellulose, 0.1% Tween 80 and 
0.15 M HCl, and administered in a volume of 1 ml on the 
morning of study by oral gavage using an 18 gauge curved 
blunt needle (Popper and Sons, New Hyde Park, N.Y.). One 
ml of vehicle alone was administered for control experi 
ments. HCl was added to the vehicle to insure an acid 
environment in the stomach in all studies. Preliminary 
experiments showed that 23 mg/kg piroxicam consistently 
produced ulceration, and this dose was used in all subse 
quent studies. Four hours after the administration of NSAID 
or vehicle, rats were euthanized with sodium pentobarbital 
(100 mg/kg IP), and the surface area of ulceration per 
stomach was quantitated using morphometric techniques. 
Stomachs were removed, the lumen was exposed by an 
incision along the radius of greater curvature, and the 
stomach was washed in phosphate buffered saline. The 
luminal surface was laid out on a ?at surface with gross folds 
removed by gentle distension. The percentage of surface 
involved with submucosal hemorrhage was then determined 
by point counting, as described by Weibel, E. R. Stereologi 
cal Methods: Practical Methods for Biological Morphom 
etry. Academic Press, New York 1980. This was done by 
tabulation of the percentage of points over ulcerations using 
a point counting eyepiece graticle (16x16 points in a square 
format). At the 22x magni?cation used on the Wild dissect 
ing microscope (Wild-Heerbrugg, Basel, Switzerland), the 
graticle covered a 1 cm2 area of the surface. Four to ?ve 
non-overlapping sampling sites were taken to fully cover the 
exposed surface. To determine the total luminal surface area, 
the outline of the outer boundary of the stomach was traced 
using a transparent acetate sheet, and the area was deter 
mined from planimetry. The surface area of ulcerated 
regions per stomach was then determined by multiplying the 
surface density of ulceration regions by the luminal surface 
area of the stomach. 
MEASUREMENT OF LIPID PEROXIDATION IN 
STOMACHS. 
Lipid peroxidation is studied in piroxicam~and vehicle 
treated rat stomachs by measuring thiobarbituric acid (TBA) 
reactivity of gastric punch biopsies by the method of Buege 
and Aust Buege, J. A., Aust, S. D. Methods Enzymol 
5l:302—310 (1978). Four hours after piroxicam or vehicle, 
stomachs are opened along the radius of greater curvature, 
washed with ice cold normal saline, and spread along a ?at 
surface with lumens exposed. Five punch biopsies from 
mucosa] through serosal surfaces are taken from each stom 
ach using a 3 mm diameter skin biopsy punch. Biopsies are 
taken over ulcers in piroxicam treated stomachs and ran 
domly over gastric rugae (where ulcers occur) in vehicle 
control stomachs. Biopsies from each stomach are com 
bined, homogenized on ice in 1 ml of cold 1.15% KCl, and 
mixed with 2 ml of TBA reagent (0.375% thiobarbituric acid 
and 15% trichloroacetic acid in 0.25 HCl, to which 0.01% 
butylated hydroxytoluene is added just prior to use). After 
incubation at 100° C. for 15 minutes, the mixture is cooled 
and centrifuged at 1,500 g for 10 min. The absorbance of the 
supernatant is measured at 532 nm, and results expressed as 
A532 per stomach. 
MEASUREMENT OF GLUTATl-IIONE IN 
GASTRIC MUCOSA. 
Gastric mucosa] glutathione is measured in piroxicam 
and vehicle-treated rat stomachs. Four hours after piroxicam 
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or vehicle, stomachs are opened, washed with ice cold 
saline, and spread along a flat surface with lumens exposed. 
The gastric mucosa is then removed by scraping with a 
surgical blade. The mucosa is homogenized on ice in 1 ml 
of 1.15% KCl. Two aliquots of 250 p1 are snap frozen in 
liquid nitrogen and stored at —70° C. for later determination 
of total glutathione by the method of Anderson, M. E. 
Methods Enzymol 113:548-555 (1985) and protein by a 
modi?cation of the Lowry method, described by Bennett, J. 
P. Techniques Lipid Membrane Biochem. B408z1-22 
(1982), using bovine serum albumin as a standard. Results 
are expressed as nmole/mg protein. To measure oxidized 
glutathione (GSSG), the remaining 500 pl is mixed with an 
equal volume of N-ethylmaleimide (NEM) in water (10 mM 
?nal concentration of NEM), snap frozen and stored at -70° 
C. After thawing for analysis, this mixture is passed over at 
C-18 Sep-Pak column (Waters Associates, Milford, Mass.) 
and washed with 1 ml phosphate buffer (pH 7.5). This 
technique for removing excess NEM has been previously 
shown to result in >90% recovery of GSSG. GSSG is then 
assayed by the method used above to determine total glu 
tathione. 
MEASUREMENT OF GASTRIC XANTHINE 
OXIDASE ACTIVITY. 
Xanthine dehydrogenase (XDH) and oxidase (X0) activi 
ties are measured in whole stomach from piroxicam-treated 
and vehicle-treated rats, using methods reported by Parks, 
et. al. Am. J. Pathol. 254 (Gastrointest Liver Physiol 17): 
G768—G774 (1988). The artifactual conversion of XDH to 
X0 is minimized by quickly removing stomachs from rats 
that were anesthetized with 50 mg/kg sodium pentobabital 
and still breathing spontaneously. After gastrectomy, the rats 
are euthanized by cutting the abdominal aorta. Stomachs are 
quickly rinsed in an ice cold homogenizing buffer consisting 
of 50 mM potassium phosphate buifer, pH 7.0, containing 10 
mM dithiothreitol (DTT), l mM phenylmethylsulfonyl ?uo 
ride (PMSF) and 0.1 mM EDTA. The stomach is then 
immediately immersed in liquid nitrogen and ground to a 
fine powder under liquid nitrogen using a mortar and pestle. 
About 0.5 g of frozen powder is added to 5 ml of homog 
enizing buffer and centrifuged 40,000 g for 30 min. The 
supernatant is decanted and rnicrofuged for an additional 10 
min. Supernatants are not stored but assayed less than 2 
hours after collection to prevent loss of activity. 
The spectrophotometric assay used is based on production 
of uric acid at 295 nm (lambda295=l.l z l04M_1cm_'). To 
increase reaction rates activity was measured at 30 rather 
than 25° C. One ml reaction mixtures contained 500 pl 
sample, 50 M xanthine and 100 M EDTA in 50 mM 
potassium phosphate buffer, pH 7.8 X0 is assayed in the 
absence in NAD+, while XDH +X0 activity is measured in 
the presence of 500 M NAD+. Enzyme activities are 
reported as international units (1 pmol of urate formed per 
min.). The extent of XDH conversion (% X0) is calculated 
from X0 activity divided by XDH+X0 activity. 
Studies of Mitochondrial Respiration. 
Rat liver mitochondria are prepared using the method of 
Lai and Clark Methods Enzymol 55:5l—60 (1979). The 
livers are excised rapidly into ice cold isolation medium 
containing 0.25M sucrose, 10 mM tn's(hydroxymethyl)ami 
nomethane (Tris), 0.25% bovine serum albumin (fatty acid 
free), and 0.5 mM potassium EDTA, pH 7.4. The tissue is 
minced and rinsed three times in cold isolation medium. The 
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minced tissue is placed in a Dounce homogenizer with 20 ml 
cold isolation medium, gently homogenized, and diluted 
with an additional 10 ml of isolation medium. The homo 
genate is centrifuged at 2,000 g for 3 min., and the resulting 
supernatant recentrifuged at 12,500 g for 8 min. The crude 
mitochondrial pellet is suspended in 0.12M mannitol-0.03M 
sucrose medium containing 3% Ficoll, gently layered onto 
20 ml of 6% Ficoll (0.25M mannitol-0.06M sucrose), and 
centrifuged at 11,500 g for 30 min. The resulting mitochon 
drial pellet is resuspended in the isolation medium and 
recentrifuged for 10 min. at 12,000 g. The ?nal pellet is 
brought to a concentration of 10 to 15 mg of mitochondrial 
protein per ml with isolation medium. Mitochondrial protein 
is determined by the Biuret reaction described by Gornall, A. 
G., et al. Biol Chem 1771751-766 (1949), using bovine 
serum albumin as a standard. Mitochondrial respiration is 
measured polarographically in a magnetically stirred cham 
ber at 25° C., using a Clark rnicroelectrode (Diamond 
Electro-tech, Ann Arbor, Mich). The incubation medium 
contains the following (in mM): 5K+, 226 mannitol, 75 
sucrose, 5 Tris~phosphate, l0 Tris-Cl, and 0.05 EDTA at pH 
7.4. State 4 respiratory rates are determined using both 
NADH-linked (2.5 mM malate+2 rnM glutamate) and 
FADl-lz-lined (10 mM succinate) substrates, with 5 mM KCl 
at pH 7.0. State 3 respiration rates are measured after 
stimulation with 1.5 mM ADP. Respiratory control ratios are 
determined as the ratio of State 3 to State 4 respiration after 
incubation with 0, 50, 100 and 200 11M piroxicam. 
Studies of Microsomal Lipid Peroxidation. 
Microsomes are isolated from rat livers by modi?cation of 
the method of Fleisher and Kervina, Methods Enzymol 
3117-41 (1974). Rats are euthanized by C02 narcosis. The 
livers are excised rapidly into cold isolation medium con 
taining 0.1M sodium phosphate and 2 mM EDTA, pH 7.4. 
The tissue is minced and homogenized in 3 ml isolation 
medium per gram of tissue using a Potter-Elvehjarn homog 
enizer. The homogenate is centrifuged at 17,800 g for 20 
min., and the pellet discarded. The supernatant is recentri 
fuged at 100,000 g for 60 min. The resulting pellet is 
resuspended in isolation buifer and recentriguged at 100,000 
g for 40 min. The ?nal pellet is resuspended in storage buffer 
containing 100 mM potassium phosphate, 20% glycerol, 1 
mM EDTA, 1 mM DTT and 20 M butylated hydroxytolu 
ene, pH 7.25. This suspension is frozen under liquid nitrogen 
and stored at —70° CL until use. Microsomal protein is 
determined by a modi?cation of the Lowry method of 
Anderson, M. E. Methods Enzymol ll3:548—555 (1985). 
The effect of 200 M piroxicam on microsornal lipid per 
oxidation is studied by incubating l mg microsomal protein 
in 100 mM potassium phosphate, pH 7.25, on a shaking 
water bath at 37° CL for 90 min., with and without the 
addition of 2 mM NADPH or 1 rnM EDTA. Lipid peroxi 
dation in the 1 ml reaction mixture is measured by mixing 
with 2 ml TBA reagent and assaying for thiobarbituric acid 
reactivity by the method of Buege and Aust. Values are 
expressed as the increase in absorbance at 532 nm (A532) per 
mg microsornal protein and represent the mean of three 
replicates. 
Statistical Analysis. 
Di?'erences in total luminal surface area in cmz, surface 
area of ulcerated regions per stomach and bio-chemical 
analyses between each treatment intervention and its corre 
sponding untreated control group are compared using the 
Mann-Whitney U Test, Dixon, W. 1., Massey, F. J., Jr. 
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Introduction to statistical methods, 4th edition. (New York: 
McGraw Hill, 1983). The effect of treatment interventions 
on NSAID-induced ulceration are displayed graphically as 
% of control ulceration, determined by summing the ratios 
of cm2 ulceration in each treatment stomach to the mean cm2 
ulceration of respective untreated N SAID control stomachs, 
and multiplying +100. In vitro studies are compared using 
the Student’s unpaired T-test, Dixon, W. J., Massey, F. J ., Jr. 
Introduction to statistical methods, 4th edition. (New York: 
McGraw Hill, 1983). Values are expressed as meaniSEM. 
Signi?cance is assumed when P<0.05. 
Reagents and Pharmaceuticals 
Phenyl N-tert-butyl nitrone is obtained from Aldrich 
Chemicals, Milwaukee, Wis. All other chemicals and phar 
maceuticals are from Sigma Chemical. Piroxicam caused 
profound gastric ulceration. FIG. 1 shows that piroxicam 
induced ulcers usually occurred only on the ridges of gastric 
rugae and spread linearly along these ridges, without 
involvement of the remaining gastric surface area. In the 
absence of an intervention, a mean of 0.215 cm2 ulceration 
was present in piroxicam-treated control stomachs. How 
ever, the degree of ulceration in this highly stress-dependent 
model was variable, ranging among experiments from 
0.0310009 to 070610.104 cmz. For this reason, each treat 
ment intervention was compared to its own group of control 
rats that were fasted simultaneously and treated with piroxi 
cam at the same time. 
EXAMPLE 2: SUPPRESSION OF 
PIROXICAM-INDUCED ULCERS BY FREE 
RADICAL SCAVENGERS. 
Piroxicam was selected as a model NSAID because it is 
highly ulcerogenic in rats and mice, yet is a relative weak 
reversible inhibitor of prostaglandin synthesis. The spin trap 
phenylbutyl nitrone (PBN) was used to explore the role of 
free radicals and oxidative events mediated by xanthine 
oxidase- and iron-mediated oxidant injury in the pathogen 
esis of piroxicam-induced gastric ulcers. In each experiment, 
the surface area of gastric ulceration produced by piroxicam 
in 15 treated rats was compared to that in 15 rats of the same 
age and size that were fasted simultaneously but which 
received no intervention. Phenylbutyl nitrone (30 mg/kg) 
was given orally in water 1 hour before piroxicam and also 
added to vehicle when piroxicam was administered. When 
intervention were given with piroxicam, the pH of the ?nal 
mixture was adjusted if necessary to equal that of piroxieam 
and vehicle alone. 
To generalize the ?ndings relative to piroxicam to other 
NSAIDS, the elfect of PBN, administered as above, can be 
compared with the e?’ect on gastric ulceration from aspirin 
(200 mg/kg), di?unisal (125 mglkg), naproxen (150 mg/kg) 
and ibuprofen (230 mg/kg). 
Piroxicarn-induced ulcers were markedly reduced in rats 
treated with free radical scavengers, as shown in FIG. 2, 
suggesting that generation of reactive oxygen species is an 
important mechanism in the pathogensis of piroxicarn-in 
duced ulcers. In ulcerations/unit area, piroxicam only pro 
duced 0229:0145 ulcerations/unit area, and piroxicam plus 
PBN produced 0.077i0.l04 ulcerations/unit area, statisti 
cally signi?cant at p<0.0052. In contrast, ascorbate, a reduc 
ing substance that is well-recognized to facilitate iron 
dependent generation of reactive oxygen species, increased 
ulceration by over 600% compared to control stomachs 
treated with piroxicarn alone (019410.039 cm2 ulceration in 
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ascorbate-treated stomachs vs 0.031i0.009 cm2 in stomachs 
receiving piroxicam alone, P<0.00l. In support of an oxidant 
mechanism as the pathogenesis of ulcers from piroxicam, 
thiobarbituric acid reactivity was signi?cantly increased in 
gastric biopsies from piroxicam treated rats compared to rats 
treated with vehicle alone (A532=0.l04iO.0l0 for piroxicam 
vs 0.075i0.004 for vehicle treated stomachs, P<0.05). 
Piroxicam also decreased total glutathione in gastric mucosa 
(03310.03 nmoles/mg protein) compared to vehicle alone 
(0.042i0.07 nmoles/mg protein) and increased the fraction 
of GSSG (8.9i0.9 for piroxicam vs 6.4 0.7% for vehicle), 
although these differences failed to achieve statistical sig 
ni?cance. 
Xanthine oxidase activity was readily identi?ed in whole 
stomach. Piroxicam treated stomachs had 30.5il.6 mU/g of 
total XHD+XO activity, of which 455% was X0. Vehicle 
treated control stomachs had 3l.6i2.45 mU/g X. Piroxicam 
increases the rate of mitochondrial oxygen uptake in the 
absence of ADP (State 4) and that normal stimulation of 
respiration by ADP (State 3) is lost in the presence of 
piroxicam. This inhibition of respiratory control by piroxi 
cam was demonstrated for both FADHZ-linked and NADH 
linked substrates. However, piroxicam did not increase 
generation of OZ-by mitochondrial respiration. Piroxicam 
had no effect on NADPH-dependent microsomal lipid per 
oxidation. 
Aspirin (0.972i-0.3l8 cmz), di?unisal (0597:0103 cmz), 
naproxen (0370:0056 cm2) and ibuprofen (0644:0110 
cmz) also caused severe gastric ulceration. In summary, 
ulceration from piroxicam was markedly inhibited by the 
spin-trap PBN. 
EXAMPLE 3: NON-TOXICITY OF PBN AND 
BIOAVAILABILITY. 
Previous studies on mutagenicity using standard tech 
niques have demonstrated that PBN and analogs thereof are 
not mutagenic. In addition, in vitro cytotoxicity tests using 
human lymphocytes have indicated that PBN in concentra 
tions of up to at least 100 prnolar have no cytotoxic elfect. 
In vivo toxicity tests have indicated the following. Acute 
doses PBN in doses up to 3 g/kg in rodents have no adverse 
e?ects. An LD50 has yet to be determined because of the lack 
of toxicity. Acute i.v. doses of PBN ranging from 10 to 300 
mg/kg body weight (injected within 60 seconds) have no 
acute toxic etfects in gerbils. Continuous i.v. administration 
of PBN at a dose of 50 mg/kg/hr for a total of 48 hr has no 
adverse effect on gerbils. 
An estimate of the bioavailability of PBN demonstrates 
that it is widely available throughout the body and is able to 
cross all of the barriers to distribution, including the blood 
brain barrier (the brain shows 80% of the plasma concen 
tration). Limited pharmokinetic studies indicate that the 
plasma half-life in the rat is three to four hours. 
Modi?cations and variations of the present invention, 
compositions containing PBN and derivatives thereof, and 
methods using the compositions for the treatment or pre 
vention of gastric ulceration resulting from ingestion of 
non-steroidal anti-in?ammatories, will be obvious to those 
skilled in the art from the foregoing detailed description. 
Such modi?cations and variations are intended to come 
within the scope of the following claims. 
We claim: 
1. A method for in vivo treatment or prevention of gastric 
ulceration from ingestion of non-steroidal antiinllammato 
ries comprising: 
O 
t... 5 
25 
35 
40 
45 
SO 
60 
65 
12 
administering to a patient in need of such treatment 
ot-phenyl t-butyl nitrone [and derivatives] or a deriva 
tive thereof [having spin-trapping activity and prevent 
ing ATP depletion in vivo in tissue] having the formula: 
Y Y 
wherein: 
X is phenyl or 
(OR)n 
wherein R is H, 
Y 
and n is a whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group; and 
a pharmaceutically acceptable carrier for oral administra 
tion to a patient, in a dosage effective to treat or prevent 
gastric ulceration from ingestion of nonsteroidal anti 
inflammatory compounds. 
2. The method of claim 1 wherein the phenyl butyl nitrone 
derivatives are selected from the group consisting of 
hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl PBNs, 
alkoxyl PBNs, phenyl PBNs. 
3. The method of claim 1 wherein the PBN derivative is 
functionalized to release in vivo a compound selected from 
the group consisting of 2-, 3-, and 4-hydroxyphenyl t-butyl 
nitrone; 2-, 3-, and 4-hydroxyphenyl t-butyl nitrone; 2-, 3-, 
4-carboxyphenyl t-butyl nitrone; and 2-, 3-, and 4-ami 
nophenyl t-butyl nitrone. 
4. The method of claim 1 comprising as the active 
ingrdient ot-phenyl t-butyl nitrone. 
Re. 35,213 
13 
5, The method of claim 1 wherein the PBN [and deriva 
tives] or a derivative thereof is in a pharmaceutical carrier 
delivering an effective dosage to a patient to treat or prevent 
gastric ulceration from simultaneous ingestion of nonsteroi 
dal antiin?ammatory compounds. 
6. The method of claim 1 wherein the PBN [and deriva 
tives] or a derivative thereof is in a pharmaceutical carrier 
delivering an effective dosage to a patient to treat or prevent 
gastric ulceration from subsequent ingestion of non-steroi 
dal anti-inllammatoriy compounds. 
7. The method of claim 6 wherein the non-steroidal 
anti-in?ammatory is selected from the group consisting of 
aspirin, acetaminophen, ibuprofen, piroxicam, naproxen, 
?ufenamic and methanamic acid and related nonsteroidal 
antiin?ammatory compounds. 
8. The method of claim 1 wherein the PBN [and deriva 
tives] or a derivative thereof is provided in a dosage of 
between 3 and 300 mg PEN/kg body weight. 
9. The method of claim 8 wherein the PBN[and 
derivaties] or a derivative thereof is provided in a dosage of 
between 10 and 30 mg/kg body weight. 
10. The method of claim 1 wherein the PBN [and deriva 
tives] or a derivative thereof is provided in combination 
with a pharmaceutical carrier selected from the group con 
sisting of microcapsules, liposomes, immobilizing sub 
strates, salts that are poorly absorbed through the gas 
trointestinal lining, oils, and buffering agents. 
11. A composition for in vivo treatment or prevention of 
gastric ulceration comprising: 
Ot-phenyl t-butyl nitrone [and derivatives] or a derivative 
thereof [having spintrapping activity and preventing 
ATP depletion in vivo in tissue] having the formula: 
H O 
\ / 
GIN» 
Y Y 
wherein: 
X is phenyl or 
(0R)n 
wherein R is H, 
o 0 
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and n is a whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
or Z; and 
Z is a C1 to CS straight or branched alkyl group; and 
a pharmaceutically acceptable carrier for oral administra 
tion to a patient, wherein the a-phenyl t-butyl nitrone 
[and derivatives] or a derivative thereof is in a dosage 
elfective to prevent or treat gastric ulceration by non 
steroidal antiin?amrnatory compounds wherein the 
PBN [and derivatives] or a derivative thereof is in 
combination with a non-steroidal anti-in?ammatory, 
said agents being present in effective amounts. 
12. The composition of claim 11 wherein the phenyl butyl 
5 nitrone derivatives are selected from the group consisting of 
40 
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hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl PBNs, 
alkoxyl PBNs, phenyl PBNs. 
13. The composition of claim 11 wherein the PBN deriva 
tive is functionalized to release in vivo a compound selected 
from the group consisting of 2-, 3-, and 4-hydroxyphenyl 
t-butyl nitrone; 2-, 3-, and 4-hydroxyphenyl t-butyl nitrone; 
2-, 3-, and 4-carboxyphenyl t-butyl nitrone; and 2-, 3-, and 
4-aminophenyl t-butyl nitrone. 
14. The composition of claim 11 comprising as the active 
ingredient ot-phenyi t-butyl nitrone. 
15. The composition of claim 11 wherein the PBN [and 
derivatives] or a derivative thereof is in a pharmaceutical 
carrier delivering an effective dosage to a patient to prevent 
injury from simultaneous ingestion of a non-steroidal anti 
in?ammatory compound. 
16. The composition of claim 11 wherein the non-steroi 
dal anti-in?ammatory is selected from the group consisting 
of aspirin, acetaminophen, ibuprofen, piroxicam, naproxen, 
?ufenamic and methanamic acid and related nonsteroidal 
antiin?ammatory compounds. 
* * * * * 
